Treatment of psoriatic arthritis with secukinumab: a case series
Aim: Psoriatic arthritis (PsA) is a chronic inflammatory disorder affecting up to 30% of psoriatic patients, worsening patients’ quality of life. Secukinumab, a fully humanized monoclonal antibody that selectively inhibits interleukin (IL) 17 A, has been recently approved for the treatment of PsA in...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-11-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2018.1527994 |